720 related articles for article (PubMed ID: 29658792)
1. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.
Müller C; Domnanich KA; Umbricht CA; van der Meulen NP
Br J Radiol; 2018 Nov; 91(1091):20180074. PubMed ID: 29658792
[TBL] [Abstract][Full Text] [Related]
2. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative.
Müller C; Zhernosekov K; Köster U; Johnston K; Dorrer H; Hohn A; van der Walt NT; Türler A; Schibli R
J Nucl Med; 2012 Dec; 53(12):1951-9. PubMed ID: 23139086
[TBL] [Abstract][Full Text] [Related]
3. Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside.
Van Laere C; Koole M; Deroose CM; de Voorde MV; Baete K; Cocolios TE; Duchemin C; Ooms M; Cleeren F
Theranostics; 2024; 14(4):1720-1743. PubMed ID: 38389843
[TBL] [Abstract][Full Text] [Related]
4. Production and Use of the First-Row Transition Metal PET Radionuclides
Chaple IF; Lapi SE
J Nucl Med; 2018 Nov; 59(11):1655-1659. PubMed ID: 30262514
[TBL] [Abstract][Full Text] [Related]
5. Promising Scandium Radionuclides for Nuclear Medicine: A Review on the Production and Chemistry up to In Vivo Proofs of Concept.
Huclier-Markai S; Alliot C; Kerdjoudj R; Mougin-Degraef M; Chouin N; Haddad F
Cancer Biother Radiopharm; 2018 Oct; 33(8):316-329. PubMed ID: 30265573
[TBL] [Abstract][Full Text] [Related]
6. Cross section measurement of terbium radioisotopes for an optimized
Dellepiane G; Casolaro P; Favaretto C; Grundler PV; Mateu I; Scampoli P; Talip Z; van der Meulen NP; Braccini S
Appl Radiat Isot; 2022 Jun; 184():110175. PubMed ID: 35344829
[No Abstract] [Full Text] [Related]
7. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with
Baum RP; Singh A; Benešová M; Vermeulen C; Gnesin S; Köster U; Johnston K; Müller D; Senftleben S; Kulkarni HR; Türler A; Schibli R; Prior JO; van der Meulen NP; Müller C
Dalton Trans; 2017 Oct; 46(42):14638-14646. PubMed ID: 28825750
[TBL] [Abstract][Full Text] [Related]
9. Future prospects for SPECT imaging using the radiolanthanide terbium-155 - production and preclinical evaluation in tumor-bearing mice.
Müller C; Fischer E; Behe M; Köster U; Dorrer H; Reber J; Haller S; Cohrs S; Blanc A; Grünberg J; Bunka M; Zhernosekov K; van der Meulen N; Johnston K; Türler A; Schibli R
Nucl Med Biol; 2014 May; 41 Suppl():e58-65. PubMed ID: 24360901
[TBL] [Abstract][Full Text] [Related]
10. Comparison between Three Promising ß-emitting Radionuclides, (67)Cu, (47)Sc and (161)Tb, with Emphasis on Doses Delivered to Minimal Residual Disease.
Champion C; Quinto MA; Morgat C; Zanotti-Fregonara P; Hindié E
Theranostics; 2016; 6(10):1611-8. PubMed ID: 27446495
[TBL] [Abstract][Full Text] [Related]
11. First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced
Singh A; van der Meulen NP; Müller C; Klette I; Kulkarni HR; Türler A; Schibli R; Baum RP
Cancer Biother Radiopharm; 2017 May; 32(4):124-132. PubMed ID: 28514206
[No Abstract] [Full Text] [Related]
12. Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals.
Notni J; Wester HJ
J Labelled Comp Radiopharm; 2018 Mar; 61(3):141-153. PubMed ID: 29143368
[TBL] [Abstract][Full Text] [Related]
13.
Dellepiane G; Casolaro P; Mateu I; Scampoli P; Voeten N; Braccini S
Appl Radiat Isot; 2022 Nov; 189():110428. PubMed ID: 36049443
[TBL] [Abstract][Full Text] [Related]
14. Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging.
Favaretto C; Talip Z; Borgna F; Grundler PV; Dellepiane G; Sommerhalder A; Zhang H; Schibli R; Braccini S; Müller C; van der Meulen NP
EJNMMI Radiopharm Chem; 2021 Nov; 6(1):37. PubMed ID: 34778932
[TBL] [Abstract][Full Text] [Related]
15. Optimization of reaction conditions for the radiolabeling of DOTA and DOTA-peptide with (44m/44)Sc and experimental evidence of the feasibility of an in vivo PET generator.
Huclier-Markai S; Kerdjoudj R; Alliot C; Bonraisin AC; Michel N; Haddad F; Barbet J
Nucl Med Biol; 2014 May; 41 Suppl():e36-43. PubMed ID: 24361353
[TBL] [Abstract][Full Text] [Related]
16. A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies with
Talip Z; Favaretto C; Geistlich S; Meulen NPV
Molecules; 2020 Feb; 25(4):. PubMed ID: 32093425
[TBL] [Abstract][Full Text] [Related]
17. Cutting edge rare earth radiometals: prospects for cancer theranostics.
Sadler AWE; Hogan L; Fraser B; Rendina LM
EJNMMI Radiopharm Chem; 2022 Aug; 7(1):21. PubMed ID: 36018527
[TBL] [Abstract][Full Text] [Related]
18. Imaging quality of (44)Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET.
Bunka M; Müller C; Vermeulen C; Haller S; Türler A; Schibli R; van der Meulen NP
Appl Radiat Isot; 2016 Apr; 110():129-133. PubMed ID: 26774390
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Labeling of Plasma Proteins for Imaging of Enhanced Vascular Permeability in the Lungs.
Schniering J; Borgna F; Siwowska K; Benešová M; Cohrs S; Hasler R; van der Meulen NP; Maurer B; Schibli R; Müller C
Mol Pharm; 2018 Nov; 15(11):4995-5004. PubMed ID: 30265552
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
